<DOC>
	<DOC>NCT01654185</DOC>
	<brief_summary>The addition of dimethyldiguanide might increase the efficacy of AI treatment in metastatic breast cancer.</brief_summary>
	<brief_title>Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer</brief_title>
	<detailed_description>The addition of dimethyldiguanide might increase the efficacy of AI in patients with metastatic breast cancer after the failure of the first line endocrine therapy.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>postmenopausal HR positive breast cancer patients; inoperable locally advanced or metastatic breast cancer patients; candidate for endocrine therapy; ECOG equal to or less than 1; adequate bone marrow function(Hb&gt;=90g/L, WBC &gt;=3.5×10^9/L,ANC&gt;=1.5×10^9/L, PLT&gt;=80×10^9/L; adequate renal function(Ccr&lt;=ULN);adequate liver function(ALT,AST,AKP&lt;=2.5*ULN,or &lt;=5*ULN if liver metastases) life expectancy &gt;=12weeks; no severe history disease of liver,heart,lung or kidney; written informed consent form; Her2 overexpression; patients who has visceral endocrisis；</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>